Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响

doi:10.19438/j.cjoms.2022.04.009

中国口腔颌面外科杂志 ›› 2022, Vol. 20 ›› Issue (4): 366-370.doi: 10.19438/j.cjoms.2022.04.009

Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响

赵小妹^*, 夏荣辉^*, 钟来平^#, 朱东旺^#, 张志愿

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院, 国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2022-03-14 修回日期:2022-05-20 出版日期:2022-07-20 发布日期:2022-07-20
通讯作者: 朱东旺,E-mail: zhudongwang@yeah.net;钟来平,E-mail: zhonglaiping@163.com。^#共同通信作者
作者简介:赵小妹（1973-）,女,本科,主管护师,E-mail: zhaoxiaomei9th@163.com;夏荣辉（1985-）,男,博士研究生,副主任医师,E-mail: xiatonghui12345@126.com。^*并列第一作者
基金资助:
国家自然科学基金（81602370）; 上海交通大学医学院附属第九人民医院医院管理项目（YGB202111）

Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma

ZHAO Xiao-mei, XIA Rong-hui, ZHONG Lai-ping, ZHU Dong-wang, ZHANG Zhi-yuan

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2022-03-14 Revised:2022-05-20 Online:2022-07-20 Published:2022-07-20

摘要/Abstract

摘要： 目的: 检测核转录相关因子2（Nrf2）在口腔鳞癌组织中的表达,探讨其对TPF诱导化疗效果的影响。方法: 选择65例接受TPF诱导化疗的口腔鳞癌患者,采用免疫组织化学方法检测患者活检肿瘤标本中Nrf2的表达,分析Nrf2表达与患者基线资料及预后的关系。采用SPSS 23.0软件包对数据进行统计学分析。结果: 生存分析发现,口腔鳞癌患者Nrf2表达与TPF诱导化疗预后显著相关,Nrf2低表达者较高表达者具有更好的总生存率、无疾病生存率、局部无复发生存率、无远处转移生存率。单因素及多因素Cox风险模型分析发现,Nrf2是口腔鳞癌患者TPF化疗的独立预后风险因素。结论: Nrf2表达与口鳞癌患者TPF诱导化疗疗效相关,Nrf2低表达患者预后更好,Nrf2可作为预测口腔鳞癌患者TPF诱导化疗效果的生物标志物。

关键词: Nrf2, 口腔鳞癌, TPF诱导化疗, 预后

Abstract: PURPOSE: To examine the expression of nuclear factor erythroid-2 related factor (Nrf2) in oral squamous cell carcinoma (OSCC) and investigate the effect of Nrf2 on TPF induced chemotherapy. METHODS: A total of 65 patients with OSCC who received TPF chemotherapy were selected. Nrf2 expression in the biopsy specimens before treatment was examined by immunohistochemistry. The correlations between Nrf2 expression and clinical factors and clinical response to TPF induced chemotherapy were analyzed. SPSS 23.0 software package was used for data analysis. RESULTS: Survival analysis showed that Nrf2 expression was significantly correlated with the prognosis of TPF induced chemotherapy in OSCC patients. Patients with higher Nrf2 expression had better overall survival, disease-free survival, local relapse-free survival and distant metastasis free survival. Univariate and multivariate Cox analysis showed that Nrf2 was an independent prognostic risk factor for TPF chemotherapy in OSCC patients. CONCLUSIONS: The expression of Nrf2 is correlated with the efficacy of TPF induced chemotherapy in OSCC patients. Patients with low Nrf2 have a better prognosis, and Nrf2 can be used as a biomarker to predict the efficacy of TPF induced chemotherapy in OSCC patients

Key words: Nrf2, Oral squamous carcinoma, TPF induced chemotherapy, Prognosis

中图分类号:

R739.8

赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.

ZHAO Xiao-mei, XIA Rong-hui, ZHONG Lai-ping, ZHU Dong-wang, ZHANG Zhi-yuan. Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2022, 20(4): 366-370.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[2] Chinn SB, Myers JN.Oral cavity carcinoma: current management, controversies, and future directions[J]. J Clin Oncol, 2015, 33(29): 3269-3276.
[3] Sun W, Zhao T, Aladelusi TO, et al.Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2021, 50(8): 795-802.
[4] Lorch JH, Goloubeva O, Haddad RI, et al.Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial[J]. Lancet Oncol, 2011, 12(2): 153-159.
[5] Posner MR, Hershock DM, Blajman CR, et al.Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1705-1715.
[6] Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1695-1704.
[7] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[8] Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer[J]. Cancer Cell, 2018, 34(1): 21-43.
[9] Tebay LE, Robertson H, Durant ST, et al.Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease[J]. Free Radic Biol Med, 2015, 88(Pt B): 108-146.
[10] Kang KA, Hyun JW.Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance[J]. Toxicol Res, 2017, 33(1): 1-5.
[11] Bai X, Chen Y, Hou X, et al.Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters[J]. Drug Metab Rev, 2016, 48(4): 541-567.
[12] Zhong LP, Zhu DW, William WN, et al.Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease[J]. Mol Cancer Ther, 2013, 12(6): 1112-1121.
[13] Trachootham D, Alexandre J, Huang P.Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?[J]. Nat Rev Drug Discov, 2009, 8(7): 579-591.
[14] Ma Q.Role of Nrf2 in oxidative stress and toxicity[J]. Annu Rev Pharmacol Toxicol, 2013, 53: 401-426.
[15] Menegon S, Columbano A, Giordano S.The dual roles of NRF2 in cancer[J]. Trends Mol Med, 2016, 22(7): 578-593.

Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响

Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏姿尚, 崔文丽, 张梦云, 姚志涛. 口腔鳞状细胞癌患者颈部淋巴结特征与预后的关系[J]. 中国口腔颌面外科杂志, 2023, 21(1): 41-48.
[2]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[3]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.
[4]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[5]	许刚, 宋其义, 蒋卫东, 刘景秀. 水通道蛋白3在口腔鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 478-482.
[6]	杨宋, 王宁, 赵树超, 李恒勇, 葛胜优, 周凯, 宋凯, 尚伟, 冯元勇. Chemerin在合并2型糖尿病口腔鳞癌患者肿瘤中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(4): 390-395.
[7]	张益益, 杨玥怡, 琚梧桐, 钟来平. 局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(4): 413-416.
[8]	魏东亮, 李智, 鞠侯雨, 吴云腾, 郭伟, 任国欣. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
[9]	杨金刚, 夏荣辉, 朱云, 吴思成, 董亚兵, 杨功鑫, 史俊隆, 崔迎慧, 朱凌, 周晌辉. 98例原发性颌骨内鳞状细胞癌预后影响因素的回顾性分析[J]. 中国口腔颌面外科杂志, 2022, 20(3): 239-243.
[10]	孙大为, 张云, 朱勇. shRNA干扰Rce1基因表达对口腔鳞癌细胞放射敏感性的影响[J]. 中国口腔颌面外科杂志, 2022, 20(2): 123-128.
[11]	努尔曼古丽·牙森, 多力昆·吾甫尔, 白尔娜·吾守尔, 闫广鹏. 血清IL-6、IL-17、TNF-α和IFN-γ水平与60例口腔鳞癌患者临床特征关系探讨[J]. 中国口腔颌面外科杂志, 2022, 20(2): 141-145.
[12]	陈一铭, Ahmed, 季彤, 任振虎. 101例头颈部横纹肌肉瘤临床、病理及预后分析[J]. 中国口腔颌面外科杂志, 2022, 20(2): 146-150.
[13]	瞿楚翔, 孙树洋, 张志愿. 从遗传异质性认识口腔鳞癌的侵袭过程[J]. 中国口腔颌面外科杂志, 2022, 20(2): 193-197.
[14]	王育新, 王志勇, 王永功, 王慧明, 王丽珍, 田皞, 叶金海, 付坤, 阮敏, 孙长伏, 孙国文, 刘法昱, 许碧云, 后军, 刘冰, 刘亮, 陈永锋, 陈占伟, 肖灿, 李思毅, 李志勇, 李勇, 李楠, 张陈平, 张东升, 张胜, 张凯, 杨溪, 何巍, 苏彤, 季彤, 林李嵩, 罗瑞华, 赵志立, 胡勤刚, 唐瞻贵, 徐蔚嘉, 黄志权, 黄晓峰, 梁玉洁, 韩正学, 韩伟, 蒋灿华, 喻建军, 蔡志刚, 廖贵清, 廖圣恺, 蔡惠明, 魏建华. 吲哚菁绿荧光成像技术在口腔鳞癌治疗中的应用：中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(1): 1-6.
[15]	李行, 许飞虎, 杨云博, 韩楠男, 阮敏. 口腔鳞癌腮腺淋巴结转移的临床病理特征与预后分析[J]. 中国口腔颌面外科杂志, 2022, 20(1): 28-31.